Small RNA molecules can participate in complex regulatory networks not merely through Watson-Crick interactions with other RNAs (as in anti-sense RNA), but also by forming discrete structures that bind protein or low-molecular weight targets. RNA aptamers derived from in vitro selections (SELEX) are being used inside cells for at least four purposes: (1) to antagonise normal cellular proteins as a means of elucidating their biological roles; (2) as decoys to natural RNA-binding proteins to reveal their functions or those of structural elements within naturally occurring transcripts; (3) as regulatory modules to govern the expression of exogenous genes; and (4) to antagonise disease-related targets for potential biomedical applications. This paper summarises recent advances in each of these areas, the parameters that influence successful application and the potential for future developments. The use of aptamers in vivo may serve as a paradigm for understanding how some non-coding RNAs and other elements of the ribonome exert their influence on the intracellular proteome, and is thus becoming an important tool for modern cell and molecular biology.
INTRODUCTION
There is a new appreciation for the diverse roles played by RNAs both in vitro and inside cells, where the ribonome and proteome intertwine in a beautiful dance whose choreography we are only beginning to understand. Natural transcripts are rarely present in cells as naked RNA. Instead, they quickly acquire an entourage of specifically and non-specifically bound proteins. These RNA-protein interactions not only govern the flux of each RNA through a cell's information processing machinery, in many cases they are also essential for the functions of the proteins; well-known examples include telomerase, spliceosomes and tRNA processing enzymes, and proteins involved in the processes of X-chromosome inactivation and translational regulation. The ribonome and the proteome are thus inextricably interconnected. The richness of RNA function is inadequately captured by simple reference to the overt categories of mRNA, tRNA and rRNA. Instead, it is more useful to think in terms of individual RNA structural domains or modules and to define whether these modules function by acting in cis to regulate genetic information flow (eg by modulating mRNA transport or stability), or whether they serve as independent structural elements that assemble into ribonucleoproteins (RNPs). The ability to dissect protein-interactive regions of the RNA into discrete modules and to engineer new biologically active modules is a recurrent theme of this paper.
There has been an explosion in the number of RNAs isolated in vitro that bind specific ligands or catalyse specific chemical reactions. [1] [2] [3] Ligand-binding RNAs selected in vitro are referred to as aptamers. Because they bind their targets with affinities and specificities similar to those of antibody Fab fragments, aptamers have tremendous potential for participation in biology. This paper examines the effects of expressing aptamers inside cells, both in terms of the impact on cell physiology and in terms of aptamer function. Some of the insights into biological systems gained from such experiments will also be discussed. Wherever possible, quantitative information obtained in vitro is correlated with the observed biological outcomes, although a complete quantitative understanding is still elusive in most cases. Examples are drawn from the literature in which aptamers have been used in four contexts: first, to antagonise normal cellular proteins as a means of elucidating their biological roles; second, as decoys to natural RNA-binding proteins to reveal their functions or those of structural elements within naturally occurring transcripts; third, as regulatory modules to govern the expression of exogenous genes; and, fourth, to antagonise diseaserelated targets for potential biomedical applications. The following sections outline 16 cases in which aptamers have been inserted into cells, usually by intracellular transcription from foreign DNA. A number of biochemical and mechanistic questions that surround the use of aptamers in cells are discussed, and the challenges and prospects for future developments in this field are presented. This review does not cover anti-sense approaches to gene inactivation, posttranscriptional gene silencing (PTGS) or RNA interference (RNAi), aptamers targeted against extracellular proteins, aptamers or ribozymes with non-RNA backbones (such as ribose 29 modification or phosphorothioate substitution), or the use of ribozymes to target intracellular RNA cleavage. Excellent recent reviews of these topics can be found in refs. 4-17. 
ANTAGONISING NORMAL CELLULAR PROTEINS
Binding of an RNA aptamer to its protein target often inhibits the activity of that protein in vitro. Since these RNAs have their origins in test-tube evolution experiments, there is no a priori reason why they should retain their functions inside cells. In vitro, the RNAs experience denaturing gel electrophoresis, hightemperature unfolding and refolding steps, and carefully controlled buffer conditions, while inside cells they experience dense macromolecular crowding and ionic environments that are difficult to reproduce in vitro, and they are usually transcribed with flanking sequences not present during their original isolation. Yet, the experiments below demonstrate that many in vitro-derived RNAs continue to recognise their targets when transcribed inside cells. These experiments also highlight the importance of dosage and specificity.
RNA Pol II and transcription
Thomas et al. selected RNA aptamers that bind RNA polymerase II holoenzyme from the yeast Saccharomyces cerevisiae. 18 One aptamer, designated FC, bound the Pol II with a dissociation constant (Kd) of 20 nM, versus 180 nM for the original random pool for a very modest nine-fold improvement in binding affinity. While aptamer FC inhibits Pol II transcription initiation, it has no effect on Pol II elongation. Specificity is further demonstrated by the fact that it does not inhibit in vitro transcription by Pol I or Pol III from S. cerevisiae or by Pol II from Schizosaccharomyces pombei. To monitor Pol II inhibition in S. cerevisiae cells, the DNA-encoding aptamer FC was cloned downstream of the natural Pol IIIdependent RNaseP RNA promoter (RPR1) and expressed along with an 84-nucleotide leader in yeast cells (Figure 1) . The large subunit of Pol II was then placed under control of the LEU2 promoter. When these cells are grown on leucine-rich medium, transcription from the LEU2 promoter is suppressed, resulting in decreased Pol II levels, although cell growth is not affected. 18, 19 Cells that expressed the Pol II aptamer grew normally on plates with low leucine medium, but their growth was markedly slowed on high leucine plates. Interestingly, aptamer expression in RNA aptamers can be used to inhibit a protein's function to help elucidate its biological function otherwise wild-type cells does not affect cell growth.
These results highlight two important aspects of moving aptamers into cells. First, aptamers can retain their binding and inhibitory activity without the special handling they receive in vitro. Second, it is critical to balance the levels of aptamer accumulation, target expression level and the cell's sensitivity to target concentration. The fact that Pol II inhibition by the aptamers only affects cell growth when Pol II is limiting suggests both that the aptamer is able to titrate only a given amount of the Pol II and that Pol II levels are normally well in excess of this amount. Yeast cells can continue to grow slowly even with only ten per cent of the normal 10,000-14,000 copies of Pol II, 19, 20 and aptamer FC is expressed rather poorly in these constructs (0.03 per cent of total RNA). Since Pol II is normally present in excess of minimal cellular needs, inactivation of a large fraction of the Pol II might have no observable effects on growth and thereby escape experimental detection. The contrary case may hold for proteins that are present at concentrations near their minimal threshold for biological activity (such as some regulatory proteins). For these proteins, it may be particularly effective to use aptamers to titrate their intracellular levels.
Leukocyte adhesion and intracellular signalling cascades
The â2 integrin LFA-1 (for 'lymphocyte function-associated antigen') functions in adhesion of leukocytes during immune and inflammatory responses by binding to intercellular adhesion molecules ICAM-1, -2 or -3 present on the surfaces of target cells. LFA-1 activation occurs through an intracellular signalling cascade that can include cytohesin-1. The Famulok laboratory generated aptamers to LFA-1 and cytohesin-1. 21, 22 The cytohesin-1 aptamer bound the Sec7 domain of cytohesin-1 with a Kd of 16 nM but did not measurably recognise Sec7 domains in other guanine-nucleotide-exchange factors (GEFs). In contrast, the LFA-1 aptamers selected against a 43-residue peptide from the intracellular domain of LFA-1 bound relatively weakly, with Kd values around 500-1000 nM. To dissect the roles of each protein in leukocyte adhesion, Jurkat E6 cells were transfected with plasmids encoding aptamers to either LFA-1 or cytohesin-1 under the control of the phage T7 RNA polymerase promoter. The expressed RNAs carry a stabilising hairpin flanking the 59 side and a strong stem-loop terminator for the T7 polymerase on the 39 side (Figure 2 ). In this system, transcription of the aptamers is absolutely dependent on co-transfection with a second vaccinia virus that encodes the phage T7 polymerase. As the viral DNA is transcribed in the cytoplasm immediately on infection, the expression construct does not need to carry nuclear export signals.
Expression of aptamers to either target resulted in reduced phorbol ester-induced adhesion of Jurkat E6 cells to surfaces derivatised with ICAM-1, while control Figure 1 : Design of the expression system used for in vivo synthesis of yeast RNA Pol II-binding aptamers. 18 Top: the Pol III-dependent RPR1 promoter controls aptamer expression. Bottom: in yeast strain YF1971, levels of active RNA Pol II holoenzyme are dependent on the level of expression of the large subunit of RNA Pol II encoded by the RPO21 gene. Addition of leucine to the growth medium reduces expression of the LEU2 promoter, thus decreasing RNA Pol II activity to a level at which inhibition by the aptamer causes a growth defect
aptamers had no effect on cell adhesion. The cytohesin-1 aptamer was further shown to induce gross alterations in cell morphology, while expression of control RNA had no effect. Fluorescence in situ hybridisation (FISH) microscopy suggested that aptamer expression redirects F-actin organisation. Cytohesin-1 is a member of the class of GEF family of proteins for human ADP-ribosylation factors (ARFs). The Sec7-binding aptamer inhibited GDP/GTP exchange by ARF-1 in vitro. Until recently, it was not possible to determine whether cytohesin-1 or some other small GEF was responsible for intracellular signalling, due in part to the lack of specific inhibitors for the small GEFs. Because the cytohesin-1 aptamer showed no detectable interaction with any other cellular protein, its effectiveness in this expression system was instrumental in establishing the participation of cytohesin-1 in LFA-1-mediated leukocyte adhesion.
The aptamers to LFA-1 illustrate the fact that quantitative relationships observed in vitro do not always explain satisfactorily the observed biological effects. Given the authors' assumption of 10 6 copies of the LFA-1 aptamers per cell and, assuming a cell volume of approximately 10 À11 litres, we calculate an overall concentration of about 160 nM, which is below the in vitro Kd for the LFA-1 aptamers. This calculation seems to suggest that only a fraction of the Sec7 domains of the â integrin LFA-1 need to be occluded by inhibitory aptamers to result in modulation of the intracellular signalling cascade. This could be accomplished, for example, if the cell is exquisitely sensitive to the aggregatetransduced signals -then, a modest titration or upregulation would push it across a response threshold. Yet, the uncertainty in this estimate is large, and further investigation will be needed to establish quantitative relationships and biological mechanisms.
Exportin 1/CRM1 and RNA export to cytoplasm RNA export from the nucleus to the cytoplasm uses GTP-dependent pathways that include exportins, RanGTP and adapter proteins possessing binding sites for both the RNA and the exportin. The Rev protein of human immunodeficiency virus (HIV)-1 directs the export of partially spliced and unspliced viral RNA from the nucleus to the cytoplasm for translation of structural proteins and for packaging into new viruses. Revdependent export appears to share the same pathway as 5S rRNA and capped U1 snRNA. Expression of Rev's leucinerich nuclear export signal (NES) coupled to BSA blocks cap-dependent export of 5S rRNA and capped U1snRNA, as well as Rev-dependent export of a reporter RNA, although it does not inhibit the export of mRNA, tRNA or ribosomal subunits. 23 Hamm et al. 24 isolated RNA aptamers to an antibody that also binds to the Rev NES. The aptamers thus mimic the structure of the Rev NES well enough to bind the same antibody ( Figure 3 ). The authors next investigated whether the aptamers were also functional mimics. Coinjection of one aptamer and capped export substrates into Xenopus oocyte nuclei inhibited the cytoplasmic accumulation of capped substrates. Similar results were observed when NES peptide was co-injected with the reporter RNA or when the aptamer was transcribed in vivo from the hU6 promoter (an RNA pol III promoter -note that Pol III transcripts lack the 59 cap structure required for mRNA export to the cytoplasm). This aptamer therefore seemed to be acting in an anti-idiotype manner by mimicking the behaviour of the Rev NES to which the original antibody had been raised. Furthermore, the aptamers themselves were exported into the cytoplasm. The anti-idiotype hypothesis was later confirmed when the intracellular binding target for the aptamer was identified as CRM1 (also known as exportin 1). 25 Rev can form a stable complex with CRM1, which is thought to mediate Rev-dependent export of HIV transcripts. NES peptide displaced the aptamer from CRM1 and also from the anti-NES antibodies, showing that the NES peptide and the aptamer share overlapping binding sites on both CRM1 and the antibodies against the peptide. The aptamer thus appears to be both a structural and functional mimic of the Rev NES peptide.
The results above are complicated by the fact that aptamer variants that failed to bind to the anti-NES antibody were also found in the cytoplasm. 24 If they are reaching the cytoplasm by passive diffusion through the nuclear pores, or if they can access another transport pathway, the same mechanism may account for the apparent active transport of the active aptamer. Furthermore, CRM1-Ran-aptamer complexes are not observed in vitro. Because of the pervasive role that Ran plays in traffic through the nuclear pores, the inability to observe a complex between all three components is puzzling. The authors suggest that the stringency of the co-immunoprecipitation assays used to monitor Ran binding may be significantly greater than that required to effect nuclear export in vivo. 25 This is another quantitative argument for which the numbers needed to evaluate it are not yet available.
DISSECTING THE FUNCTIONS OF RNA-BINDING PROTEINS AND OF STRUCTURAL ELEMENTS IN NATURAL TRANSCRIPTS SelB translational elongation factor
The amino acid selenocysteine (Sec) is required for normal function in a small number of proteins, including formate dehydrogenase. In Escherichia coli, the H isoform of formate dehydrogenase Anti-idiotype functional mimicry of HIV-1 Rev NES peptide by an RNA Figure 3 : Anti-idiotype behaviour of aptamer that mimics the structure and function of HIV-1 Rev NES-peptide. 24, 25 (A) The antibody used as the binding target for aptamer selection was itself targeted to bind the HIV-1 Rev nuclear export signal (NES) peptide. (B) The CRM1 protein normally binds Rev NES to direct nuclear export. CRM1 also binds the selected aptamer, and this RNA can displace Rev NES peptide from CRM1. This result indicates that NES and the RNA aptamers share overlapping binding sites. Thus, the aptamers are acting as structural mimics of the Rev Nes-peptide. The aptamer also blocks NES-directed protein export in Xenopus oocytes, showing that it also acts as a functional mimic contains an internal UGA codon at which Sec is incorporated during translation. The tRNA that is charged with Sec enters the ribosomal A-site bound to SelB, a specialised elongation factor that is closely related to EF-Tu. The normal termination function of the UGA codon is suppressed in the presence of a stable hairpin structure (termed fdhF) immediately 39 adjacent to UGA. It is this hairpin that binds SelB ( Figure 4A ). The translational read-through is portable; Klug et al. 26 inserted the fdhF hairpin and an in-frame UGA into the lacZ gene, and, in this context, observed translational read-through of lacZ in vivo. A collection of fdhF variants was then selected from a degenerate library in which the original sequence was mutagenised to a level of 30 per cent per position. Although all of the selected RNAs bound SelB with equivalent affinity in vitro, only a few of them supported translational read-through of the in-frame UGA in cis, and these were only marginally altered from the parental sequence ( Figure 4B ).
It appears, then, that the fdhF hairpin has a second biological function beyond simply tethering SelB to the mRNA, 26, 27 although it should be kept in mind that the authors did not determine explicitly whether the aptamers folded properly in vivo by ascertaining, for instance, whether the aptamers could block read-through of the wild-type fdhF by acting as decoys when expressed in trans. The authors speculate that fdhF may trigger a conformational change in SelB that promotes delivery of the SelB/SectRNA Sec /GTP ternary complex into the ribosomal A-site. 26 An alternative possibility is that, when the ribosome encounters a UGA codon, there is a kinetic competition between normal termination and recruitment of the SelB ternary complex. The wild-type fdhF hairpin may suppress binding of release factors in a manner that the variant aptamers -selected solely on the basis of SelB binding -are unable to mimic. Either way, this work illustrates the power of using aptamers inside cells to distinguish binding events from the other functions of a given RNA.
Human La antigen and polypyrimidine tract-binding protein in HCV IRES-mediated translation
When the plus strand RNA genome of hepatitis C virus (HCV) enters a cell, translation of a 3010 amino acid polyprotein is initiated at an internal ribosome entry site (IRES) that occupies most of the 341 nucleotides in the 59 non-coding region. The IRES binds to the 40S subunit of the ribosome where it induces significant structural changes that appear to clamp down on the mRNA. 28, 29 Several ancillary factors are believed to facilitate translation from the IRES in vivo, including polypyrimidine tract-binding protein (PTB) and a protein known as the La antigen. La antigen binds directly to Ability to bind SelB in vitro does not predict ability to substitute for fdhF element in vivo 
the IRES and stimulates IRES-mediated translation in vitro. 30 The IRES also forms ultraviolet crosslinks with PTB, 31 possibly mediated by one or more of three polypyrimidine tracts in the IRES.
To explore the functional significance of these binding interactions, aptamers selected against La and PTB were isolated and shown to disrupt cap-independent translation in rabbit reticulocyte lysates. 32, 33 Translation was rescued by the addition of excess protein target. Capdependent translation, which operates through a different mechanism, was either not inhibited or only slightly inhibited, depending on the aptamer used. When these RNAs were co-transfected into a human liver cell line (Huh7) along with an HCV IRES-luciferase reporter construct, luciferase translation in the presence of aptamer was decreased to 15-25 per cent of the levels observed when an unrelated RNA was cotransfected in place of the aptamer. 32, 33 Together, these data help to establish the biological importance of La antigen and PTB for achieving maximal HCV IRESmediated translation. In the absence of measured aptamer-target dissociation constants and intracellular concentrations of both RNAs and their targets, it is difficult to derive quantitative interpretation of this work. Nevertheless, the principle is demonstrated that aptamer antagonists can be used in vivo to elicit a biological effect in a manner akin to the biochemical effects commonly observed through antibody pull-down experiments in vitro.
B52 Drosophila SR protein, premRNA splicing and fly development SR proteins are required for both constitutive and alternate pre-mRNA splicing. Overexpression of the Drosophila SR protein B52 (homologous to the human SRp55) causes severe developmental defects, while its deletion is dominant lethal in the second instar stage of larval development. Shi, Hoffman and Lis 34 selected a family of aptamers that bind B52 with Kd values of 20-50 nM. Comparative sequence analysis, deletions and nuclease sensitivities defined the binding core in the aptamers to be a shared, simple hairpin-loop element with eight nucleotides in the loop, and a stem that could be of nearly any base-paired sequence. For expression in vivo, 35 five copies of this element were transcribed in a tandem, pentavalent array ( Figure 5 ). The ends of the array were flanked by complementary sequences that form an eight base pair stem known as the 'S35 element', which had been previously shown to increase dramatically the accumulation of a chimaeric ribozymetRNA construct. 36 To produce defined ends, the authors included hammerhead ribozyme sequences on each end of the array, on the assumption that self-cleavage would occur on transcription, releasing the mature array. This cleavage event would also remove the 59 cap and polyadenylation signal, thereby encouraging nuclear accumulation. The individual aptamers in the array displayed an average Kd of 50 nM, while the apparent Kd for the pentavalent array was around 5 nM. To increase accumulation of the mature form, multiple copies of the array were expressed in tandem, separated by self-cleaving hammerhead ribozymes. The authors calculate that in vivo expression from an inducible Pol II promoter (Cu 2þ -inducible metallothionein promoter or heat-shock promoter) should yield an intranuclear concentration in excess of 100 nM. When expressed in cultured S2 or Kc cells, the array accumulated to about 0.1 per cent of total RNA. These aggregate numbers may not be relevant, however, since the RNA does not seem to reach a uniform distribution before seeking out its target. Instead, B52 protein is recruited to sites of array transcription, as demonstrated by in situ hybridisation to the polytene chromosomes of Drosophila salivary glands. 35 Yet, the relevance of polytene chromosomes, with their hundreds of transcribing loci, may not be representative of other tissues. There are still unresolved questions about the localisation of the B52-aptamer interaction and the quantitative significance of bulk Kd values.
The developmental effects of expressing the inhibitory aptamer array are profound. In transgenic flies that carry the aptamer array but which are otherwise wild type, survival to adulthood was reduced by 50 per cent, while, in flies engineered to overproduce B52, aptamer expression rescued most of the developmental defects associated with its overexpression. Thus, this aptamer array produces a conditional allele that can titrate intracellular levels of B52 protein, either to convert a normal fly into one with a partial null (lethal) phenotype, or to rescue excessive expression that would otherwise be damaging or lethal. These observations again highlight the importance of balancing expression levels of aptamer and target to achieve a particular net activity in the target protein.
REGULATION OF EXOGENOUS GENES AND OTHER APPLICATIONS
The studies above clearly show that aptamers selected in vitro can retain their target-recognition features when expressed inside cells or delivered through transfections in cell culture. This section examines how in vivo expression of aptamers has been used to elucidate biological processes and other applications.
Ligand-regulated translation in bacteria
Translational initiation in bacteria requires base pairing between the purine-rich ribosome-binding sequence (RBS) in the mRNA and the 39 end of the 16S rRNA. Occluding the RBS by binding a protein or by formation of mRNA secondary structure is known to repress translation. The Belasco group has exploited this fact to study RNA-protein interactions by cloning a candidate RNA (such as the HIV Rev recognition element, RRE) immediately adjacent to the RBS of a reporter gene (reviewed in ref. 37 ). Binding of the target protein (in this case, Rev) prevents recognition of the RBS sequence by the ribosomal small subunit, repressing translation of the reporter protein. 38 Following a similar strategy (Figure 6 ), the authors recently cloned aptamers selected to bind HIV reverse transcriptase (RT) [39] [40] [41] 
Ligand-regulated translation in eukaryotes
Aptamers that bind small-molecule targets often derive much of their structural integrity through stabilising interactions with the bound ligand, and they are unstructured in the absence of the ligand. [42] [43] [44] Werstuck and Green 45 sought to regulate eukaryotic translation by making use of this structural stabilisation. Cap-dependent translation of eukaryotic mRNAs requires binding of the eIF4F complex to the cap structure, recruitment of the small (40S) ribosomal subunit and scanning along the 59 untranslated region (UTR) to the first AUG start codon. The authors also described aptamers that specifically bind either tobramycin or kanamycin A, two structurally related aminoglycoside antibiotics. When three copies of the tobramycin-binding aptamer were inserted into the 59 UTR of a reporter gene, cap-dependent translation in wheat germ extract was near normal when no antibiotic was present, but was reduced to ten per cent of the control activity in the presence of 60 ìM tobramycin. No inhibition by tobramycin was observed when the 59 UTR carried no aptamer or when 60 ìM kanamycin was used in place of tobramycin.
The three copies of the antibiotic aptamer in the 59 UTR were then replaced with three copies of an aptamer selected to recognise H33258 and H33342, two related Hoechst dyes, and similar ligand-dependent translational repression in wheat germ extracts was observed. Unlike the aminoglycosides, the dyes are permeable to cells and were non-cytotoxic. Chinese hamster ovary (CHO) cells were transfected with DNA encoding a lacZ gene with a 59 UTR that either did or did not carry three copies of the aptamer to the Hoechst dyes. Addition of the dye 24 hours after transfection reduced â-galactosidase activity to five to ten per cent of that observed without the dye. In the absence of dye-binding aptamers in the 59 UTR, neither â-galactosidase nor luciferase activity (from a co-transfected control DNA) was affected by addition of the dye, demonstrating that the dye itself had no global effect on translation. Using a Embedded within preexisting mRNA design similar to that of Werstuck and Green, 45 one may be able to incorporate aptamers to cell-permeable dyes into the 59 UTRs of constructs intended for use in gene therapy applications. Activity of the exogenous gene could thereby be regulated (either positively or negatively) through small-molecule therapeutics whose dosage could easily be monitored and adjusted by a clinical physician.
Natural gene regulation through RNA-small-molecule interactions
Aptamers to small molecules also retain their function when expressed in bacterial cells. The aptamers to tobramycin and kanamycin noted above 45 allowed bacterial cells to grow at otherwise lethal concentrations of antibiotic, with more vigorous growth observed when three copies were expressed together than when one was expressed alone. While there are many examples of natural mRNAprotein complexes that regulate gene expression, to date there is no proven example of gene regulation through direct mRNA-small-molecule interactions. Prime candidates for such regulation may lie in the 59 UTRs of several bacterial genes involved in the biosynthesis of three common metabolic co-factors. First, Miranda-Ríos et al. 46 have described a 38-nucleotide RNA structural element (thi box) conserved in the upstream portions of several thiamin biosynthesis genes across many bacteria. When the thi box is inserted into the 59 UTR of lacZ, â-galactosidase activity is repressed on addition of thiamin to the growth medium. No protein factor has yet been identified that binds the thi box, and overexpression of the RNA element does not titrate any limiting protein factor in the cell to relieve repression by thiamin. Miranda-Ríos et al. propose that this RNA element binds thiamin directly, blocking translation initiation. Second, an analogous 25-nucleotide conserved element (the 'B 12 ' box) is found in the long 59 UTR of cobalamin-metabolising btuB and cob operon genes. 47, 48 In the presence of cobalamin, it is thought that direct translational repression by sequestering the ribosome-binding sites of the btu and cob genes takes place. Again, no trans-acting factor other than cobalamin has been observed. It has been proposed that the co-factor binds directly to the B 12 box to effect regulation, 46 and there are preliminary data from the Breaker lab showing in vitro nuclease protection in this RNA in the presence of B 12 (A. Nahvi and R. Breaker, personal communication). Finally, conserved RNA structural elements have also been observed upstream of some riboflavin genes. 49 These may also act as regulated translational repressors in a similar fashion to that proposed for the thi and B 12 boxes.
Genomic SELEX
One means of identifying the biological RNA targets for any given protein or small molecule is to perform a SELEX experiment using fragments of genomic DNA or cDNA to construct the template for the starting library. Any RNA thus selected reflects a transcript that is found in, or that is potentially found in, the organism or tissue from which the library was made. This approach, termed 'genomic SELEX', [50] [51] [52] has identified a host of potential targets for the bacteriophage MS2 coat protein, 53 the Drosophila Tra2 54 and Sxl (H. Banejee, and R. Singh, personal communication) splicing factors, and the fragile X-related protein FMR1. 55, 56 As the authors of each of these papers rightly note, it is one thing to identify an RNA sequence that is capable of interacting with a given target, and quite another to show that the interaction occurs inside a cell or that it has biological significance. Nevertheless, this powerful approach can focus attention on a relatively small set of RNA-protein pairs that might otherwise have gone unnoticed. The favourite targets for studying aptamer-protein interactions inside cells have been 'professional nucleic acid-binding proteins', such as polymerases and splicing factors, or proteins known to bind 
Purification of ribonucleoprotein complexes
RNaseP is the enzyme that cleaves the 59 leader from pre-tRNA to yield mature tRNA. The bacterial and archaeal enzymes contain a catalytic RNA subunit and a single basic protein that assists in substrate binding, but that can be replaced with high salt in vitro. The eukaryotic enzyme was notoriously difficult to purify, in part because it contained several subunits. Engelke and co-workers inserted a streptavidin-binding aptamer into a loop of the RNA subunit of the yeast RNaseP and purified active complexes on streptavidin beads. The complexes contained ten protein subunits and one RNA, and its purification facilitated further biochemical and genetic characterisation of the eukaryotic enzyme (see ref. 65 and citations therein). While this system does not demand that the aptamer exhibits target-binding activity within a cell, it must be active in the lysates to permit purification and it must allow the rest of the complex to assemble for the purification to be of interest. This approach can be easily generalised to purify complex ribonucleoprotein assemblies.
'Three-hybrid' systems in yeast
The 'three-hybrid' system of gene activation 66, 67 is based on the 'twohybrid' screens widely used to monitor protein-protein interactions in cells.
The three-hybrid systems typically contain three components: (1) a DNAbinding domain fused with the coat protein from bacteriophage MS2; (2) a hybrid RNA carrying the candidate RNA sequence(s) and at least one MS2 binding site; and (3) a transcriptional activation domain fused to the candidate protein(s). Transcription activation is achieved through coordinated interaction of the two-hybrid proteins with structural elements in the hybrid RNA. In contrast with the SelB story above, simple tethering of the hybrid proteins through RNA-protein contact is sufficient to activate transcription. The method is powerful for identifying RNA-protein interaction pairs, it is available commercially in kit form and it is in wide use -a literature search revealed over 45 publications referencing the technique. While the three-hybrid system has been reviewed elsewhere, [67] [68] [69] one example of a three-hybrid experiment that is especially relevant to this paper is included below.
BIOMEDICAL APPLICATIONS
To date, there are no clinically available aptamers for therapeutic use inside cells, although some aptamers directed against extracellular targets, which are more accessible and require less attention to questions of delivery, are in early clinical trials. Nevertheless, the promise of using engineered RNAs inside cellsincluding both aptamers and ribozymes -has spurred the development of biotechnology companies such as NeXstar Pharmaceuticals (now Gilead Sciences), NascaCell, Noxxon Pharma AG, Archemix, Ribozyme Pharmaceuticals and others. As the examples below demonstrate, there is considerable promise that aptamers can eventually be used to treat diseases as diverse as inflammatory disease, cancer, acquired immune deficiency syndrome (AIDS) and sleeping sickness.
Affinity tag built into complex allows its purification

NFk kB transcription factor
The NFkB transcription factor binds either as a p50/p50 homodimer or as a p50/p65 heterodimer to the 'kB' DNA element in promoters associated with inflammation response, HIV transcription and prevention of apoptosis. Lebruska and Maher 70 described an aptamer that binds NFkB with a Kd of 1 nM, similar to the affinity between NFkB and the kB element in DNA. Cassiday and Maher 71 constructed an RNA expression cassette that tethered this aptamer to two copies of the MS2 coat protein-binding hairpin and showed that this hybrid RNA directs lacZ transcription in a yeast three-hybrid assay. Various aptamer designs were tested for their abilities to bind NFkB in vitro and to activate lacZ in yeast cells. Best results were obtained using a hyper-stabilised aptamer carrying a 17-base pair stem ('GC clamp'). In a separate set of studies (Cassiday and Maher, unpublished data), these authors constructed a one-hybrid gene activation system in which transcription of the HIS3 gene is under the control of an NFkB binding site. Expression of an NFkB-Gal4 activation domain fusion allows HIS3 transcription and growth on plates that contain 3-amino-1,2,4-triazole (3-AT). Coexpression of the aptamer-MS2 hairpin fusion RNA blocked HIS3 expression and growth on plates containing 3-AT, 71 suggesting that the aptamer acts as a competitive decoy to disrupt the normal DNA-binding function of NFkB. On placing the HIS3 gene under the control of a three-hybrid system, in vivo expression of a degenerate library based on the original aptamer sequence yielded several individuals with enhanced NFkB binding activity (Cassiday and Maher, unpublished data) . This is one of the first demonstrations of in vivo optimisation of an in vitro-selected RNA. This combined in vitro-in vivo approach is a powerful strategy for exploiting both the vast numbers of individual sequences that can be accessed in vitro and the genetic tools and biological context of performing the assays in vivo. It is anticipated that expression of this aptamer in human cells may interfere with NFkB-dependent transcription, perhaps by blocking inflammation response, weakening or blocking HIV transcription, and inducing apoptosis.
HIV-1 Rev protein
As noted above, the Rev protein of HIV-1 is important for RNA export from the nucleus. Symensma et al. 72 cloned the Rev-responsive element (RRE) and the gene for chloramphenicol acetyltransferase (CAT) into an intron under transcriptional control of the SV40 promoter and enhancer (Figure 7 ), then transduced this DNA into African Green Monkey cells (CV-1). When Revexpressing DNA was co-transduced, CAT activity was observed in cell lysates, demonstrating that the CAT mRNA had made its way to the cytoplasm for translation. This transport is Rev dependent, since no CAT activity was detected without the Rev-encoding DNA. The Rev-binding element (RBE) within the RRE was then replaced by Rev-binding aptamers. In isolation, these aptamers bind Rev slightly better than the RBE, and they all appear to adopt similar three-dimensional folds. 72 Under conditions of saturating Rev, two different aptamers directed Revdependent transport of unspliced mRNA from the nucleus into the cytoplasm -as measured by CAT activity assays -with efficiencies roughly equal to that of the RBE itself. Yet, when Rev was limiting, CAT activities for the aptamer constructs were as much as six-fold higher than those corresponding to the RBE constructs.
Follow-up work with a pentavalent aptamer construct in place of the entire RRE also directed Rev-dependent premRNA transport into the cytoplasm. Moreover, CAT activity increased as the valency of this artificial RRE was increased from one aptamer unit to five. 73 Rev is known to oligomerise along RNA once it binds a specific high-affinity site. The results described above may suggest Combined approach, in vitro-in vivo, for optimisation of aptamer-target interaction Polyvalent Rev decoys increased efficiency of transport to the cytoplasm with increasing numbers of copies of the Rev protein per RNA strand. Alternatively, if the transport of Rev-bound transcripts is highly efficient, these results could suggest simply that polyvalency increases the probability that a given transcript will be bound by at least one Rev molecule. Careful measurement of the amounts of aptamer -and of Rev in the nucleus and of the protein-RNA stoichiometry for each multivalent RNA -combined with effective Kd values might help to resolve the mechanistic basis for enhanced transport efficiency as a function of increased valency.
These data show that the aptamers can provide functional substitutes for the natural RBE or even the entire RRE in Rev-mediated RNA transport. Several groups have reported cellular protection from HIV-1 infections using monovalent Rev-binding oligonucleotide decoys. 74, 75 While similar direct demonstrations have yet to be provided for the Rev-binding aptamers, their abilities to promote Revmediated transport suggests that they can at least get the protein's attention.
HIV-1 reverse transcriptase
Another essential HIV-1 protein is its RT, which converts the RNA genome into double-stranded DNA that can be inserted into the host genome. Therapeutic agents directed against RT are the most widespread first line of defence for AIDS intervention, especially in developing nations. These agents rapidly lose effectiveness, however, as RT point mutations that confer drug resistance accumulate. Aptamers directed against RT block its polymerisation activity in vitro. 1, 40 Most of these aptamers fold into pseudo-knot structures that bind RT with Kd values in the low nM range, although one variant in particular has been reported with a Kd in the low pM range. 41 We have recently begun assaying the abilities of anti-RT aptamers to disrupt DNA synthesis by RT inside E. coli cells. In particular, a temperaturesensitive mutation in the DNA polymerase I gene renders the BK148 strain incapable of growth at 378C, while growth at 308C is largely unaffected. Low-level expression of RT rescues the temperature-sensitive growth. 76 This rescue can be blocked by anti-RT smallmolecule drugs if wild-type RT is used in the complementation, but not if drugresistant RT is used, 77, 78 demonstrating that its enzymatic activity is directly responsible for cell growth at 378C. To determine whether the inhibitory aptamers would similarly disrupt complementation, Nickens and Burke (unpublished data) cloned several aptamers under the control of the lac repressor and co-transformed them into E. coli strain BK148 (polA ts ) with a plasmid that expresses low levels of RT. All plasmids that expressed functional aptamers blocked growth at 378C, while the control plasmid and plasmids expressing structurally perturbed aptamers had no discernable effect on complementation by RT. Since bacterial cell growth depends on enzymatically active RT, it may be possible to select biologically relevant RT mutants that escape inhibition by the aptamers. 
Mutations in the RT could be introduced randomly throughout the protein using mutagenic polymerase chain reactionthereby modelling the random mutations that would arise in nature -or they can be focused to particular locations through site-directed methods. Further refinement of the aptamer could then yield inhibitors of the mutant forms. Attempts to protect human cells from infection by extant HIV could then include co-expression of aptamers directed against both present and future RT variants. Such a strategy, if made practical, would cut off the virus's evolutionary escape routes, preventing the emergence of resistant strains.
Trypanosomes
Homann and Göringer 79 have described aptamers that bind to the outer surface of live Trypanosoma brucei, the parasite responsible for sleeping sickness. The aptamers crosslink to a single 42 kiloDalton (kDa) protein (p42) in the 'flagellar pocket' of the trypanosome. The flagellar pocket is the organelle responsible for transporting materials into and out of the parasite, and the authors show that, while the ends of the aptamer are degraded, there is a secondary structural core that remains intact in the parasite's lysosome after endocytosis. 80 Further, they show that, when biotinylated or fluorescently tagged aptamers are endocytosed, they can shuttle cargo into the trypanosome. Random sequence RNA and a nonbinding, truncated form of the aptamer do not promote uptake of the biotin or fluorescent tag. The transferrin receptor in the flagellar pocket is a heterodimer that includes the 42 kDa protein, ESAG 7. While this may be the binding target for this aptamer, high concentrations of transferrin did not interfere with aptamer binding or fluorescence. 80 Thus, while this aptamer itself does no damage to the trypanosome, it could be engineered to carry some other cargo designed to kill the parasite.
CONCLUSIONS
The examples above highlight several important themes regarding in vivo aptamer expression. On the one hand, there are the relationships among an aptamer's performance in vivo, its total accumulation inside the cell and its quantitative in vitro properties (such as Kd and specificity). On the other hand, there are the design of the expression vector, the endogenous RNA processing machinery and all the possible effects of aptamer expression on cell growth and morphology. Further elucidation of these themes should enable continued insights into cell biology and suggest new biomedical therapeutic strategies. Some of the conclusions that are apparent at this point for seven such themes are summarised below.
First, expression of nucleic acid aptamers in cells is generally compatible with retention of their biochemical activity, so long as the appropriate secondary structures are maintained. In some of the more complex aptamers, tertiary contacts are also important, although most are not so structurally sophisticated. Intracellular efficacy may not be surprising in hindsight -but it was by no means considered inevitable before the experiments were done. One important consideration is the choice of conditions under which the in vitro selections are performed. It is well recognised that an aptamer or ribozyme may be inactivated by removing some key ingredient from the buffer or by increasing another beyond a critical value. 81 It is notoriously difficult to mimic the interior of a cell, or to know precisely which variables can be ignored. The in vitro selections described above were carried out under a wide range of buffer conditions, with magnesium concentrations varying from 1 to 6 mM, sodium from 0 to 200 mM, potassium from 3 to 200 mM, pH from 7.0 to 8.0 and counterions that included acetate, phosphate and chloride. Some selections also included trace amounts of EDTA, calcium, DTT or other ingredients. Since
Targeted transport by 'piggy-backing' into specified target organism or organelle each of these conditions has yielded aptamers compatible with intracellular use, the more important considerations may be the unique conditions found within a target compartment or cell, combined with the particular salt and pH requirements for maintaining the target protein in an active form. The extent that such conditions vary among cells or within cellular compartments suggests the possibility that one might be able to select RNAs that function only under the specialised conditions in which the target is meant to be inactivated, such as the low pH of an endosome or the high calcium environment of bone tissue.
Second, target binding in vivo usually either allows the engineered RNA to take on the role of the target's normal substrate, or it turns the RNA into a competitive decoy to disrupt that target's function. The concept of RNA molecules that act as decoys inside cells is not new. One well-known natural example is that of autogenous regulation of translation, which has been observed in the synthesis of ribosomal proteins, 82 bacteriophage T4 DNA polymerase protein 83 and many other cases. Autogenous regulation is a feedback inhibition mechanism wherein excess protein binds to its own mRNA to halt further translation. Eukaryotic 5S rRNA exhibits a related phenomenon; when it accumulates beyond the levels needed for ribosome biogenesis, it binds to transcription factor TFIIIA and prevents its own transcription. When aptamers are expressed in vivo as decoys for proteins that are under autogenous regulation, the temporary drop in intracellular concentration of the target may result in stimulation of its de novo synthesis. In such cases, the observed effects may only be transient or even difficult to discern.
Third, the fraction of the target bound by an aptamer is determined by an ensemble of many quantifiable factors. These include time-dependent and steady-state molar concentrations of the aptamer (determined by synthesis and degradation rates), affinity for target, nonspecific association with other cellular components, binding stoichiometry relative to the target, intracellular localisation, and the rates of synthesis, turnover and covalent modification of the target itself. All of these components are inter-related. An aptamer that shows a 100-fold preference for one protein over another will still saturate both targets if its concentration is more than 100 times the lower Kd value. Few studies on aptamers in vivo include much quantitative information of this sort, preventing a detailed mechanistic understanding of the biophysics behind the biology. This is unfortunate, since the fraction of bound target -and presumably the degree of functional ablation -can be a profound determinant of whether a phenotypic effect is observed. For some proteins, a partial titration notably reduces its net activity (eg B52 protein and the â2 integrin LFA-1). For others, a progressive titration of the observed biological effects is evident on increasing aptamer expression levels or fraction ablation (yeast Pol II transcription, PTB/HCV IRES-mediated translation, Revmediated transport). If there are several isoforms of a target protein -due to alternative splicing patterns, multiple alleles or variable covalent modifications -and only one of these forms is intended to be antagonised, it may be necessary to fine tune both relative affinities and aptamer expression level. These considerations will be important whether one wishes to intervene in a cell's metabolism for therapeutic purposes (either to fix it or kill it) or to study the effects of functionally ablating the target.
Fourth, non-coding RNAs may bind to effect the regulation of protein activity by binding directly to those proteins, either to activate or inhibit them. Hundreds of non-coding RNAs have recently been uncovered in surveys of expressed RNA. 84, 85 While many of these are thought to regulate gene expression by anti-sense interactions with their target mRNAs, others have no known function. Systematic genome-wide surveys such as those using genomic SELEX [50] [51] [52] [53] [54] [55] [56] may be instrumental in revealing any aptamer-like RNA regulatory networks.
Fifth, design of the expression system can be as important as design of the aptamer itself. Successful appropriate expression vectors have been derived from vaccinia virus, transduced plasmid DNA, stably integrated DNA, attenuated viruses, reagents that induce endocytosis (as in the trypanosome p42 aptamers) and other vehicles. Promoter choice not only influences transcription levels and regulation, but also directs the nascent transcript to be capped and exported to the cytoplasm (Pol II promoters) or retained in the nucleus (Pol III promoters). Furthermore, the total amount of RNA in a given cell will depend not only on synthesis, but also on degradation. Therefore, structural modules that increase stability, such as the S35 element (used in the aptamers to the Drosophila B52 splicing factor), 35, 36 are likely to find their way into many of the forthcoming expression systems. The expressed RNA itself can be decorated with sequence or structural elements that direct its transport, stability and other features, and it can be expressed in single copy or as a polyvalent array. Additional discussion of expression vector design is available in refs. 86-89. Sixth, while clinical and biomedical application of aptamers in cells will need to address the basic science questions above, they will also need to grapple with the daunting challenge of specific delivery to target cells. For example, while inducing apoptosis in a tumour cell would be highly desirable, systemic apoptosis would be catastrophic. Specially engineered, non-infectious (attenuated) viruses may be useful in this regard, along with liposomal systems or even naked, stabilised RNA.
Finally, it is noteworthy that nearly all aptamers described to date either inhibit their target protein or have no effect on its function; 90 few, if any, activate their target. A possible exception may lie in the Trypanosome p42 aptamer, which appears to activate endocytosis in the parasite. 80 It may prove challenging to search specifically for aptamers that activate their targets, since it is really the RNAdependent activity of the target, rather than the simple ligand-binding activity, that must serve as the basis of the selection. Nevertheless, this may offer an exciting direction for future research. 
